JAK

Janus kinase



Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes.

JAK Inhibitors & Modulators

(3R,4S)-Tofacitinib

Cat. No.: HY-40354D

Bioactivity: (3R,4S)-Tofacitinib is an enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with **IC_{50}** of 1 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg



(3S,4R)-Tofacitinib

Cat. No.: HY-40354B

Bioactivity: (3S,4R)-Tofacitinib is an enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with **IC_{50}** of 1 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg



(3S,4S)-Tofacitinib

Cat. No.: HY-40354C

Bioactivity: (3S,4S)-Tofacitinib is the S-enantiomer of Tofacitinib. Tofacitin ib inhibits **JAK3** with **IC_{50}** of 1 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg



ASN-002

Cat. No.: HY-103018

Bioactivity: ASN-002 is a potent dual inhibitor of spleen tyrosine kinase (**SYK**) and janus kinase (**JAK**) with **IC_{50}** values of 5-46 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



AT9283

Cat. No.: HY-50514

Bioactivity: AT9283 is a multi-targeted inhibitor with **IC_{50}**s of 1.2 nM, 1.1 nM for **JAK2** and **JAK3**, respectively, a nd is also potent to Aurora A, Aurora B and Abl(T315I).

Purity: 99.13%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



AZ960

Cat. No.: HY-10411

Bioactivity: AZ960 is a potent and specific inhibitor of the **JAK2** kinas e with a **K_i** of 0.45 nM.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 2 mg, 5 mg, 10 mg, 50 mg



AZD-1480

(AZD1480; AZD 1480)

Cat. No.: HY-10193

Bioactivity: AZD-1480 is a novel ATP-competitive **JAK2** inhibitor with <b >IC $_{50}$ of < 0.4 nM, selectively against JAK3 and Tyk 2, and to a smaller extent against JAK1.

Purity: 99.37%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



AZD-4205

Cat. No.: HY-107361

Bioactivity: AZD-4205 is a selective **JAK1** inhibitor, with an **IC $_{50}$** of 73 nM, weakly inhibits JAK2, and shows little inhi bition on JAK3 (**IC_{50}**, >14.7, >30 µM, respectivel y).

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Baricitinib

(INCB028050; LY3009104)

Cat. No.: HY-15315

Bioactivity: Baricitinib is a selective orally bioavailable **JAK1**/ **JAK 2** inhibitor with **IC_{50}** of 5.9 nM and 5.7 nM, respectively.

Purity: 99.70%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Baricitinib phosphate

(INCB028050; LY3009104)

Cat. No.: HY-15315A

Bioactivity: Baricitinib phosphate is a selective orally bioavailable **JAK1< /b>/ JAK2 inhibitor with IC_{50} of 5.9 nM an d 5.7 nM, respectively.**

Purity: 99.49%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@medchemexpress.com

BMS-911543

Cat. No.: HY-15270

Bioactivity: BMS-911543 is a selective **JAK2** inhibitor, with **$IC_{5\ 0}$**s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (**IC_{50}**, 75, 360, 66 nM, respectively).

Purity: 98.03%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



CEP-33779

Cat. No.: HY-15343

Bioactivity: CEP-33779 is a novel, selective, and orally bioavailable inhibito r of **JAK2** with an **IC_{50}** of 1.8±0.6 nM.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Cerdulatinib

(PRT062070; PRT2070)

Cat. No.: HY-15999

Bioactivity: Cerdulatinib is a novel, orally available, ATP-competitive **JAK** and **SYK** inhibitor that demonstrates selective inhibiti on of TYK2 and SYK with an **IC_{50}** of 0.5 nM and 32 nM.

Purity: 99.00%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



CHZ868

Cat. No.: HY-18960

Bioactivity: CHZ868 is a type II **JAK2** inhibitor with an **IC_{50}** of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

Purity: 98.33%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



CYT387

(momelotinib)

Cat. No.: HY-10961

Bioactivity: CYT387 is an ATP-competitive inhibitor of **JAK1/JAK2** with < b>IC $_{50}$ of 11 nM/18 nM, appr 10-fold selectivity ver sus JAK3.

Purity: 98.11%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



CYT387 Mesylate

(momelotinib Mesylate)

Cat. No.: HY-10963

Bioactivity: CYT387 Mesylate is an ATP-competitive inhibitor of **JAK1/JAK2</ b> with IC_{50} of 11 nM/18 nM, appr 10-fold select ivity versus JAK3.**

Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



CYT387 sulfate salt

(momelotinib sulfate)

Cat. No.: HY-10962

Bioactivity: CYT387 sulfate salt is an ATP-competitive inhibitor of **JAK1/JA K2** with **IC_{50}** of 11 nM/18 nM, 10-fold selecti vity versus JAK3 (IC $_{50}$=155 nM).

Purity: 96.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Decernotinib

(VX-509; VRT-831509)

Cat. No.: HY-12469

Bioactivity: Decernotinib is a potent, orally active **JAK3** inhibitor, wi th **K_i**s of 2.5, 11, 13 and 11 nM for **JAK3**, JAK1, JAK2, and TYK2, respectively.

Purity: 98.91%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg



Delgocitinib

(JTE-052)

Cat. No.: HY-109053

Bioactivity: Delgocitinib is a novel and specific **JAK** inhibitor with <b >IC $_{50}$s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JA K3 and Tyk2, respectively.

Purity: 99.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Diosgenin

Cat. No.: HY-N0177

Bioactivity: Diosgenin, an important natural source of steroidal hormones, has favorable effects in the improvement of diabetes and regulation of lipid metabolism.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
50 mg



FM381

Cat. No.: HY-102046

Bioactivity: FM381 is a potent covalent reversible inhibitor of **JAK3** ta rgeting the unique Cys909 at the gatekeeper position +7 in JAK3. F M-381 has an **IC_{50}** of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respective ly.

Purity: 98.41%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GLPG0634

(Filgotinib)

Cat. No.: HY-18300

Bioactivity: GLPG0634 is a selective **JAK1** inhibitor with **IC_{50}** of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

Purity: 99.64%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GLPG0634 analog

Cat. No.: HY-13961

Bioactivity: GLPG0634 (analog) (compound176)is a pan JAK inhibitor with IC50s of 50-200 nM for JAK1/JAK2/JAK3; more information can be found in t he reference patents

Purity: 98.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg



Itacitinib

(INCB039110)

Cat. No.: HY-16997

Bioactivity: Itacitinib is a potent and selective inhibitor of **JAK1**, wi th >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.

Purity: 99.87%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Itacitinib adipate

Cat. No.: HY-16997A

Bioactivity: Itacitinib adipate is a selective **JAK1** inhibitor which has been tested for efficacy and safety in a phase II trial in myelofi brosis.

Purity: 98.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



JAK inhibitor 1

Cat. No.: HY-111471

Bioactivity: JAK inhibitor 1 is an inhibitor of **JAK** extracted from pate nt US20170121327A1, compound example 283.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

JAK-IN-1

Cat. No.: HY-13827

Bioactivity: JAK-IN-1 is a **JAK1/2/3** inhibitor with **IC_{50} b>s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.**

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



JAK3-IN-1

Cat. No.: HY-19544

Bioactivity: JAK3-IN-1 is a potent JAK3 inhibitor with IC50 of 4

Purity: 99.16%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



JAK3-IN-6

Cat. No.: HY-101976

Bioactivity: JAK3-IN-6 is a potent, selective irreversible Janus Associated Ki nase 3 (JAK3) inhibitor, with an **IC_{50}** of 0.15 nM .

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



JAK3-IN-7

Cat. No.: HY-U00390

Bioactivity: JAK3-IN-7 is a potent and selective **JAK3** inhibitor extract ed from patent WO2011013785A1, has an **IC_{50}** of <0 .01 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



JANEX-1

(WHI-P131)

Cat. No.: HY-15508

Bioactivity: JANEX-1 is a potent and specific **JAK3** inhibitor (estimated K_i=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3 -inhibitory activity (**IC 50** of 78 μM), does not i nhibit JAK1 and JAK2.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



LFM-A13

Cat. No.: HY-18009

Bioactivity: LFM-A13 is a potent **BTK**, **JAK2**, **PLK** inhibitor , inhibits recombinant BTK, Plx1 and PLK3 with **IC_{50}< /b>s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.**

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



LY2784544

(gandotinib)

Cat. No.: HY-13034

Bioactivity: LY2784544 is a potent **JAK2** inhibitor with **IC_{50}</su b>** of 3 nM. LY2784544 also inhibits FLT3, FLT4, FGFR2, TYK2, a nd TRKB with IC $_{50}$ of 4, 25, 32, 44, and 95 nM.

Purity: 98.06%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



NS-018

Cat. No.: HY-19631A

Bioactivity: NS-018 is a highly active and orally bioavailable **JAK2** inh ibitor, with an **IC_{50}** of 0.72 nM, 46-, 54-, and 3 1-fold selectivity for JAK2 over JAK1 (**IC_{50}**, 33 nM), JAK3 (**IC_{50}**, 39 nM), and Tyk2 (**IC_{50}</ sub>**, 22 nM).

Purity: >98%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



NS-018 hydrochloride

(NS018 hydrochloride; NS 018 hydrochloride)

Cat. No.: HY-19631B

Bioactivity: NS-018 hydrochloride is a highly active and orally bioavailable < b>JAK2 inhibitor, with an **IC_{50}** of 0.72 nM, 4 6-, 54-, and 31-fold selectivity for JAK2 over JAK1 (**IC_{50}< /sub>**, 33 nM), JAK3 (**IC_{50}**, 39 nM), and Tyk2 (**IC_{50}**, 22 nM).

Purity: >98%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



NS-018 maleate

Cat. No.: HY-19631

Bioactivity: NS-018 maleate is a highly active and orally bioavailable **JAK2** inhibitor, with an **IC_{50}** of 0.72 nM, 46-, 54 -, and 31-fold selectivity for JAK2 over JAK1 (**IC_{50}< /b>, 33 nM), JAK3 (IC_{50}, 39 nM), and Tyk2 (IC_{50}, 22 nM).**

Purity: 98.33%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



NSC 42834

(Z3)

Cat. No.: HY-15480

Bioactivity: NSC 42834(JAK2 Inhibitor V, Z3), a novel specific inhibitor of Ja k2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity

Purity: 95.5%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg



NVP-BSK805

(BSK 805)

Cat. No.: HY-14722

Bioactivity: NVP-BSK805 is an ATP-competitive **JAK2** inhibitor, with **I C_{50}**s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM f or JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, re spectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



NVP-BSK805 dihydrochloride

(BSK805 dihydrochloride)

Cat. No.: HY-14722A

Bioactivity: NVP-BSK805 dihydrochloride is an ATP-competitive **JAK2** inhi bitor, with **IC_{50}**s of 0.48 nM, 31.63 nM, 18.68 nM , and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

Purity: 98.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Oclacitinib maleate

(PF-03394197 maleate)

Cat. No.: HY-13577A

Bioactivity: Oclacitinib maleate is a novel **JAK** inhibitor. Oclacitinib is most potent at inhibiting **JAK1** (**IC_{50}**=10 nM).

Purity: 99.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Pacritinib
(SB1518) Cat. No.: HY-16379

Bioactivity: Pacritinib is a potent inhibitor of both wild-type **JAK2** (I C $_{50}$=23 nM) and **JAK2^{V617F}** mutant (IC<s ub>50=19 nM). Pacritinib also inhibits **FLT3** (IC $_{5\,0}$=22 nM) and its mutant **FLT3^{D835Y}** (IC $_{50}$=6 nM).

Purity: 99.66%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Peficitinib
(ASP015K; JNJ-54781532) Cat. No.: HY-19568

Bioactivity: Peficitinib is an oral **JAK** inhibitor, with **IC$_{50}$**s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2 , respectively.

Purity: 99.86%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PF-06651600
Cat. No.: HY-100754

Bioactivity: PF-06651600 is a potent **JAK3**-selective inhibitor with an < b>IC $_{50}$ of 33.1 nM.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



Pyridone 6
(CMP 6; JAK Inhibitor) Cat. No.: HY-14435

Bioactivity: Pyridone 6 is a **pan-JAK** inhibitor, which potently inhibits the JAK kinase family, with **IC$_{50}$**s of 1 nM for <b >JAK2 and **TYK2**, 5 nM for **JAK3**, and 15 nM for **JAK1**, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



RGB-286638
Cat. No.: HY-15504

Bioactivity: RGB-286638 is a **CDK** inhibitor that inhibits the kinase act ivity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E -CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35 -CDK5** with **IC$_{50}$**s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with **IC$_{50}$**s of 3, 5, 50, and 54 nM....

Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg



RGB-286638 free base
Cat. No.: HY-15504A

Bioactivity: RGB-286638 is a **CDK** inhibitor that inhibits the kinase act ivity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E -CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35 -CDK5** with **IC$_{50}$**s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with **IC$_{50}$**s of 3, 5, 50, and 54 nM....

Purity: 99.55%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Ruxolitinib
(INCB018424) Cat. No.: HY-50856

Bioactivity: Ruxolitinib is the first potent, selective **JAK1/2** inhibito r to enter the clinic with **IC$_{50}$** of 3.3 nM/2.8 nM in cell-free assays, and has > 130-fold selectivity for JAK1/2 ver sus JAK3.

Purity: 99.85%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Ruxolitinib phosphate (INCB018424 phosphate; INCB 018424 phos phate; INCB-018424 phosphate; Ruxolitinib)
Cat. No.: HY-50858

Bioactivity: Ruxolitinib (phosphate) is the first potent **JAK1/2** inhibit or with **IC$_{50}$** values of 3.3 nM/2.8 nM, more than 130-fold selectivity for JAK1/2 versus JAK3.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Ruxolitinib S enantiomer
(S-Ruxolitinib; INCB18424) Cat. No.: HY-50856A

Bioactivity: Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxo litinib is the first potent, selective **JAK1/2** inhibitor to enter the clinic with **IC$_{50}$** of 3.3 nM/2.8 nM in ce ll-free assays.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Ruxolitinib sulfate
(INCB018424 sulfateRuxolitinib) Cat. No.: HY-50859

Bioactivity: Ruxolitinib sulfate is the first potent, selective **JAK1/2** inhibitor to enter the clinic with **IC$_{50}$**s of 3.3 n M/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



SAR-20347

Cat. No.: HY-100895

Bioactivity: SAR-20347 is an inhibitor of **TYK2**, **JAK1**, **JAK2 and JAK3 with IC$_{50}$s of 0.6, 23, 26 and 41 nM, respectively.**

Purity: 97.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



SB1317

(TG02)

Cat. No.: HY-15166

Bioactivity: SB1317 is a potent inhibitor of **CDK2**, **JAK2**, and **FLT3** for the treatment of cancer, with **IC$_{50}$** of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.

Purity: 99.85%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Solcitinib

(GSK-2586184; GLPG-0778)

Cat. No.: HY-16755

Bioactivity: Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an **IC$_{50}$** of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respect ively; Solcitinib is used in the research of moderate-to-severe pl aque-type psoriasis.

Purity: 99.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



TG-101348

(Fedratinib; SAR 302503)

Cat. No.: HY-10409

Bioactivity: TG-101348 is a selective inhibitor of **JAK2** with **IC $_{50}$** of 3 nM, 35- and 334-fold more selective for JAK2 ver sus JAK1 and JAK3.

Purity: 98.28%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



TG101209

Cat. No.: HY-10410

Bioactivity: TG101209 is a selective **JAK2** inhibitor with **IC$_{50}$</ sub>** of 6 nM, less potent to **Flt3** and **RET** with < b>IC $_{50}$ of 25 nM and 17 nM, appr 30-fold selective f or JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutat ions.

Purity: 98.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Tofacitinib

(Tasocitinib; CP-690550)

Cat. No.: HY-40354

Bioactivity: Tofacitinib inhibits **JAK3** with **IC$_{50}$** of 1 nM while inhibiting **JAK2**, **JAK1**, Rock-II and Lck with **IC$_{50}$** values of 20, 112, 3400 and 3870 nM, respec tively.

Purity: 99.62%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Tofacitinib citrate

(Tasocitinib citrate; CP-690550 citrate)

Cat. No.: HY-40354A

Bioactivity: Tofacitinib citrate inhibits **JAK3** with **IC$_{50}$< /b> of 1 nM while inhibiting JAK2, JAK1, Rock-II and Lck with IC$_{50}$ values of 20 nM, 112 nM, 3,400 nM and 3,870 nM, respectively.**

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg



TYK2-IN-2

Cat. No.: HY-101762

Bioactivity: TYK2-IN-2 is an inhibitor of **TYK2**, used for treatment of i nflammatory and autoimmune diseases.

Purity: 99.41%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Upadacitinib

(ABT-494)

Cat. No.: HY-19569

Bioactivity: Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an **IC$_{50}$** of 43 nM.

Purity: 99.40%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg



WHI-P154

Cat. No.: HY-13895

Bioactivity: WHI-P154 is a potent **EGFR** inhibitor, and also modestly blo cks **JAK3**, with **IC$_{50}$**s of 4 nM and 1.8 μM, respectively.

Purity: 98.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



WHI-P97

Cat. No.: HY-11067

Bioactivity: WHI-P97 is a rationally designed potent inhibitor of JAK-3

Purity: 99.48%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



WP1066

Cat. No.: HY-15312

Bioactivity: WP1066 is a novel inhibitor of **JAK2** and **STAT3**, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and J AK3.

Purity: 99.67%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



XL019

Cat. No.: HY-13775

Bioactivity: XL019 is a potent and selective JAK2 inhibitor with IC50 of 2

Purity: 97.97%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



ZM39923

Cat. No.: HY-12589A

Bioactivity: ZM39923 is a **JAK3** inhibitor, with a **pIC$_{50}$ of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC $_{50}$ of 10 nM.**

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



ZM39923 hydrochloride

Cat. No.: HY-12589

Bioactivity: ZM39923 hydrochloride is a **JAK3** inhibitor, with a **pIC<s ub>50** of 7.1; ZM39923 hydrochloride also potently inhibi ts tissue transglutaminase (**TGM2**) with an **IC$_{50}$</sub >** of 10 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg